item management s discussion and analysis of financial condition and results of operations results of operations revenues for  and from hormone and enzyme sales were   and  respectively 
revenues in included  from a final payment from a prior research agreement 
research and development  the company s largest expense  increased in to  from  in  after increasing in from  in the increases were related to the company s manufacturing facility  including depreciation charges and expenditures for pre production salaries  the development program for the calcitonin pill  regulatory consulting fees  as well as the sponsorship of collaborative research programs for which the company spent   and  in  and respectively 
general and administrative expenses increased in to  from  in  after increasing in from  in the increase was primarily due to legal and other expenses associated with the company s ongoing financing activities 
the increase was primarily due to higher legal fees relating to licensing and joint venture negotiations and to patent matters 
interest and other income decreased  or in from after decreasing  or in from the decreases were due to a reduction in total monies available to be invested 
the company incurred  in interest expense in  up from  in this was due to increased borrowings in during the company constructed and staffed its manufacturing facility and hired regulatory consultants in the us and in europe 
during both and  the company concentrated on internally sponsored research programs and collaborations  and post research development programs  including the scale up and production of research grade calcitonin and the development of a calcitonin pill 
therefore  operating expenses increased  and cash decreased causing a decrease in interest income 
in addition  increased borrowings in increased interest expense 
as a result  the net loss increased  and  for the years ended december  and  respectively  from the prior years 
as of december   the company had available for income tax reporting purposes net operating loss carryforwards in the approximate amount of  expiring from through  which are available to reduce future earnings which would otherwise be subject to federal income taxes 
in addition  the company has investment tax credits and research and development credits in the amounts of  and  respectively  which are available to reduce the amount of future federal income taxes 
these credits expire from through the company follows statement of financial accounting standards no 
fasb  accounting for income taxes 
given the company s past history of incurring operating losses  any deferred tax assets that are recognizable under fasb have been fully reserved 
as of january  and  under fasb  the company had deferred tax assets of approximately  and  respectively  subject to valuation allowances of  and  respectively 
the deferred tax assets were generated primarily as a result of the company s net operating losses and tax credits generated 
at december   the company s deferred tax assets and valuation allowances each increased by approximately  statement of financial accounting standards sfas no 
 issued march  accounting for the impairment of long lived assets and long lived assets to be disposed of  is effective for the company beginning in the statement requires that long lived assets and certain identifiable intangibles to be held and used by an entity be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable 
an impairment loss is recognized if the sum of the expected future cash flows is less than the carrying amount of the asset 
management does not expect the implementation of sfas no 
to have a material impact on the company s financial position or results of operations  assuming successful commercialization of the company s product and or the signing of licensing joint venture agreements with pharmaceutical companies see note 
sfas no 
 accounting for stock based compensation  issued in october  established financial accounting and reporting standards for stock based employee compensation plans 
these plans include all arrangements by which employees receive shares of stock or other equity investments of the employer or the employer incurs liabilities to employees in amounts based on the price of the employer s stock 
this statement also applies to transactions in which an entity issues its equity instruments to acquire goods or services from non employees 
the company will elect the disclosure requirements only of fasb and such additional disclosure requirements are not effective for the company until liquidity and capital resources during  the company completed construction of its peptide production facility in boonton  new jersey 
the facility was constructed in a shell building that is being leased under a year net lease which began in february the company has two year renewal options as well as an option to purchase the facility 
the total cost of leasehold improvements and process equipment for this facility  including current validation costs  is approximately million 
the company is undertaking steps to secure the validation of the facility by the us food and drug administration to allow unigene to provide its calcitonin for human pharmaceutical use 
the company  at december   had cash and cash equivalents of  a decrease of  from december  during  warren p 
levy  ronald s 
levy  and jay levy  officers and directors of the company  and a member of their family loaned a total of  to the company 
a total of  of these loans is secured by liens on the fairfield plant and equipment 
in march  the company borrowed  from an unrelated third party 
this loan was paid off in may with the proceeds of a new  loan from an unrelated third party 
the new loan was on a short term basis secured by all of the assets of the company 
in connection with that loan  the members of the levy family agreed to subordinate their security interests in the fairfield plant and equipment to the secured lender and received a subordinated security interest on the equipment at the boonton plant 
this  loan was originally due on july  with interest at per annum however  it was extended to november  with an interest rate of per annum 
in november  the  loan was repaid from the proceeds of a  debt financing from two unrelated third parties collateralized by almost all of the company s assets 
in december these two parties loaned the company an additional  these loans accrue interest at a rate of per annum 
on march  this  loan was exchanged for senior secured convertible debentures in the principal amount of  the debentures mature november  and are convertible into shares of the company s common stock at a conversion rate of per share  subject to certain reset provisions 
from july through december   the company sold in private placements approximately million shares of its common stock at a price of per share  which after expenses netted the company million 
from january through march  the company sold in private placements an aggregate of  shares of common stock receiving net proceeds of  in march the company completed a private placement of million in convertible debentures 
the company received net proceeds of  as a result of this placement 
these debentures mature march  the debentures are convertible into common stock for up to one third of the principal amount on each of april   may  and june  the debentures are convertible at the lower of per share or of the market price per share of the company s common stock at the date of conversion 
the company s ability to generate additional cash from operations depends primarily upon signing research or licensing agreements  achieving defined benchmarks in such agreements  completion of plant validation  receiving regulatory approval for its products  and marketing hormones and enzyme products 
the company has signed one joint venture agreement 
however  the company has not yet received any revenue from this agreement  and there is no assurance that any revenues will be received 
the company requires additional working capital to continue its operations 
management believes that the company has sufficient cash through at least the third quarter of the company requires additional funds through financing or licensing agreements to ensure continued operations 
there is no assurance that sufficient funds will be obtained 

